Loading…
A novel RNA‐based adjuvant combines strong immunostimulatory capacities with a favorable safety profile
Protein‐ and peptide‐based tumor vaccines depend on strong adjuvants to induce potent immune responses. Here, we demonstrated that a recently developed novel adjuvant based on a non‐coding, long‐chain RNA molecule, termed RNAdjuvant®, profoundly increased immunogenicity of both antigen formats. RNAd...
Saved in:
Published in: | International journal of cancer 2015-07, Vol.137 (2), p.372-384 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Protein‐ and peptide‐based tumor vaccines depend on strong adjuvants to induce potent immune responses. Here, we demonstrated that a recently developed novel adjuvant based on a non‐coding, long‐chain RNA molecule, termed RNAdjuvant®, profoundly increased immunogenicity of both antigen formats. RNAdjuvant® induced balanced, long‐lasting immune responses that resulted in a strong anti‐tumor activity. A direct comparison to Poly(I:C) showed superior efficacy of our adjuvant to enhance antigen‐specific multifunctional CD8+ T‐cell responses and mediate anti‐tumor responses induced by peptide derived from HPV‐16 E7 protein in the syngeneic TC‐1 tumor, a murine model of human HPV‐induced cervical cancer. Moreover, the adjuvant was able to induce functional memory responses that mediated complete tumor remission. Despite its remarkable immunostimulatory activity, our RNA‐based adjuvant exhibited an excellent pre‐clinical safety profile. It acted only locally at the injection site where it elicited a transient but strong up‐regulation of pro‐inflammatory and anti‐viral cytokines as well as cytoplasmic RNA sensors without systemic cytokine release. This was followed by the activation of immune cells in the draining lymph nodes. Our data indicate that our RNA‐based adjuvant is a safe and potent immunostimulator that may profoundly improve the efficacy of a variety of cancer vaccines.
What's new?
While adjuvants can enhance immune responses induced by peptide and protein vaccines, in cancer immunotherapy, they fail to trigger the balanced, long‐lasting immunity that is needed for anti‐tumor protection. That limitation may be overcome with the development of synthetic RNA molecules as adjuvants, according to the present study. In a TC‐1 tumor mouse model, RNAdjuvant®, a novel synthetic RNA with a polymeric carrier, significantly enhanced immune responses associated with the administration of peptide vaccine. Profound anti‐tumor effects were observed. The adjuvant acted locally, at the site of injection, without inducing systemic cytokine release. |
---|---|
ISSN: | 0020-7136 1097-0215 |
DOI: | 10.1002/ijc.29402 |